Reliance on just one drug to treat the prevalent tropical disease， schistosomiasis， spurs the search for new drugs and drug targets. Inhibitors of human cyclic nucleotide phosphodiesterases (huPDEs)， including PDE4， are under development as novel drugs to treat a range of chronic indications including asthma， chronic obstructive pulmonary disease and Alzheimer's disease. One class of huPDE4 inhibitors that has yielded marketed drugs is the benzoxaboroles (Anacor Pharmaceuticals).
Reliance on just one drug to treat the prevalent tropical disease， schistosomiasis， spurs the search for new drugs and drug targets. Inhibitors of human cyclic nucleotide phosphodiesterases (huPDEs)， including PDE4， are under development as novel drugs to treat a range of chronic indications including asthma， chronic obstructive pulmonary disease and Alzheimer's disease. One class of huPDE4 inhibitors that has yielded marketed drugs is the benzoxaboroles (Anacor Pharmaceuticals).
